Cascadian Therapeutics Appoints Dr. Marc L. Lesnick as

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
50
Cascadian Therapeutics Appoints Dr. Marc L. Lesnick as Senior Vice President, Regulatory Affairs and Quality

SEATTLE, Jan. 04, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ: CASC ), a clinical-stage biopharmaceutical company, today announced the appointment of Marc L. Lesnick, Ph.D., as Senior Vice President, Regulatory Affairs and Quality where he will lead the development of global regulatory strategy and quality processes, including advancing the Company’s lead development program, tucatinib, through planned global regulatory processes to potential registration. Dr. Lesnick will be a member of the Company’s executive committee and will report to Scott Myers, President and Chief Executive Officer of Cascadian Therapeutics.

“Marc brings a wealth of product development and regulatory affairs knowledge and expertise, with multiple successful marketing applications in the United States and Europe,” said Scott D. Myers, President and CEO of Cascadian Therapeutics. “His skills and deep experience, particularly outside the United States, will help Cascadian advance tucatinib for the treatment of patients with HER2-positive metastatic breast cancer through late-stage development and U.S. and international regulatory submissions.”

Dr. Lesnick was most recently Senior Vice President, U.S. Regulatory Affairs, Global Development Projects at Shionogi, Inc., the U.S. subsidiary of Shionogi & Co., Ltd., where he led regulatory strategy for an early stage dual-tyrosine kinase inhibitor program for HER2-positive breast cancer, led the filing of a New Drug Application (NDA) for Symproic® (naldemedine) and oversaw approval and launch of Osphena® (ospemifene) in the field of women’s health. In this role, Dr. Lesnick had oversight of regulatory strategy, regulatory operations, drug safety and medical writing. In his prior role at Optimer Pharmaceuticals, he led the approval of Dificlir® (fidaxomicin) in the EU and Dificid® (fidaxomicin) in the US. Dr. Lesnick held similar positions at Verus Pharmaceuticals and PAREXEL International. Dr. Lesnick received his Ph.D. from the University of Oregon, and continued his post-doctoral studies at the University of California, San Diego, School of Medicine.

About Cascadian Therapeutics

Cascadian Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative product candidates for the treatment of cancer. The lead investigational product candidate, tucatinib, also known as ONT-380, is an oral, selective small molecule HER2 inhibitor. Cascadian Therapeutics is conducting a pivotal trial named HER2CLIMB to evaluate tucatinib versus placebo in combination with capecitabine and trastuzumab in patients with late stage HER2+ breast cancer, with and without brain metastases. Additional details can be found at www.clinicaltrials.gov (Identifier: NCT02614794) or www.HER2CLIMB.com . For more information and to sign up for email alerts or RSS feeds, please visit  www.cascadianrx.com .

Forward-Looking Statements

In order to provide Cascadian Therapeutics' investors with an understanding of its current results and future prospects, this release contains statements that are forward-looking. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include Cascadian Therapeutics' expectations regarding tucatinib clinical development activities and its potential benefits.

Forward-looking statements involve risks and uncertainties related to Cascadian Therapeutics' business and the general economic environment, many of which are beyond its control. These risks, uncertainties and other factors could cause Cascadian Therapeutics' actual results to differ materially from those projected in forward-looking statements, including the risks associated with the costs and expenses of developing its product candidates, the adequacy of financing and cash, cash equivalents and investments, changes in general accounting policies, general economic factors, achievement of the results it anticipates from its preclinical development and clinical trials of its product candidates and its ability to adequately obtain and protect its intellectual property rights. Although Cascadian Therapeutics believes that the forward-looking statements contained herein are reasonable, it can give no assurance that its expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of Cascadian Therapeutics' risks and uncertainties, you are encouraged to review the documents filed with the securities regulators in the United States on EDGAR and in Canada on SEDAR. Except as required by law, Cascadian Therapeutics does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.

All trademarks and trade names are the property of their respective owners.

Contact: Monique Greer Cascadian Therapeutics 206-801-2107 mgreer@cascadianrx.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 159

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 147

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Loyalty Programs Cut $1500 Annually for Consumers

Updated Category News Views 16

Loyalty Programs: An Essential Tool for Households In a world where every dollar counts, retail loyalty programs have become more than just a marketing strategy—they're lifelines for American households scraping through each month. According to fresh research by the Retail Industry Leaders Association (RILA) and conducted by market research leader Circana, these...

Continue Reading
LONGi's Four Paths to Global Green Development

Updated Category News Views 177

LONGi's Vision: A Cleaner, Greener Future Amidst the buzz at COP31 in Antalya, LONGi is making waves with promises of a cleaner future. They're not just throwing around eco-friendly slogans—this company's laying down real pathways to tackle climate change, one solar panel at a time. Aiming for Industrial Transformation LONGi's got their sights set on shaking up...

Continue Reading
Older Adults Embrace Cosmetic Dentistry for Confidence

Updated Category News Views 17

Why the Shift to Cosmetic Dentistry Later in Life? Aging doesn't just wrinkle your skin; it affects your smile too. Dr. Joseph T. Sumrall and Dr. Gran Sumrall, the dental gurus of Warner Robins, Georgia, are laying out why more adults are jumping on the cosmetic dentistry bandwagon as they age. Spoiler: It ain't about getting a movie-star grin but something much deeper....

Continue Reading
Hermes AI: A New Era in Market Analysis?

Updated Category News Views 21

Revolution or Just Another App? In a world where stock market insights are as cryptic as hieroglyphs to the average Joe, here comes the Hermes AI Analyzer, breaking onto the scene and promising to translate Wall Street's complex lingo into plain, simple language. It's the brainchild of Turkish engineer Umut Tugrul, who has spent decades in the trenches of software...

Continue Reading
Baidu's Q3 2026: AI Explodes Amid Marketing Slump

Updated Category News Views 35

Baidu Looks to AI as Revenue Driver in Q3 2026 You know, Baidu's got one heck of a story this quarter. Despite some clouds hanging over them, they’ve managed to find a silver lining in their AI ventures. It’s like they’ve got this magic bullet with AI Cloud growth skyrocketing 94% year over year. That’s not just a rabbit outta the hat; it’s more like pulling a...

Continue Reading
NestWorks' C500: Shaking Up CNC at Formnext 2026

Updated Category News Views 120

NestWorks C500: A Game Changer for Makers Folks, gather 'round, because NestWorks is turning heads with their C500 desktop CNC machine. As it lands firmly on TIME’s Best Inventions of 2026 list, this ain't just another gadget adorning a workshop—all eyes are on it at Formnext 2026. From November 17–20, Frankfurt is the stage where NestWorks plans to showcase how...

Continue Reading
Exploring Why Dead Outlets Stay Dead: Expert Insights

Updated Category News Views 29

The Mystery of Non-Responsive Outlets Ever found an electrical outlet refusing to cooperate when you need it most? Well, I know the frustration all too well. You'd think if the breaker ain't blown, the outlet should work like a charm. But dive into the guts of the story, and you find a series of surprises waiting to trip us up. Common Culprits: Tripped GFCIs and Loose...

Continue Reading
Jones Soda Expands into Nutrition with UCAN Deal

Updated Category News Views 145

Well, Jones Soda Co. (CSE: JSDA) is stirring the pot with its recent move to acquire the UCAN functional nutrition assets. Popped the news on November 12, 2026, and it turns out they've shelled out a cool $700,000 in cash and taken on $500,000 in liabilities for the privilege. This isn't some casual shuffle of dollars and cents—this one's a strategic gambit aimed at...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding RH's Current Market Dynamics and Trends

Updated Category News Views 195

Understanding RH's Current Market Dynamics Investors with substantial capital are adopting a decidedly bearish outlook on RH (NYSE: RH). This sentiment is crucial for retail traders who need to remain informed of market tendencies. The Unusual Options Activity Today, it's noteworthy that notable trades appeared in the public options history that we actively monitor....

Continue Reading
CHIPS® Sets New Records for Payment Transactions This Season

Updated Category News Views 333

CHIPS® Achieves a New Payment Volume Milestone On a standout day in the financial world, CHIPS cleared and settled a remarkable 1,083,550 payments valued at $2.63 trillion, marking a new daily volume record. This achievement reflects not only the significance of those transactions but also the efficiency and reliability of the CHIPS payment network. Factors Contributing...

Continue Reading
Experience Culinary Excellence at Monaco Classic Week Events

Updated Category News Views 247

Monaco Classic Week: A Blend of Sailing and Culinary Art At the heart of the mesmerizing Monaco Classic Week, a unique culinary challenge unfolded alongside breathtaking regattas. This exciting event showcases not only the beauty of vintage sailing but also the artistry in culinary creations. Chefs from various participating yachts gathered to take part in the prestigious...

Continue Reading
How Your Words Can Affect an Injury Claim

Updated Category Personal Finance Views 76

Anything you say after an accident can be used to reduce or deny your injury claim. Casual remarks like "I'm fine" or "I didn't see him" get written down, quoted back, and treated as facts about fault and injury severity. Insurance adjusters are trained to collect these statements early, while you are shaken and still guessing about your own condition. A guess you make on...

Continue Reading
Foresight Mental Health Launches Innovative Maternal Support Program

Updated Category News Views 133

Foresight Mental Health Launches Innovative Support Program Foresight Mental Health is excited to unveil its groundbreaking Maternal Mental Health Program, a comprehensive initiative aimed at providing expert mental health support across various stages of the reproductive journey. This program is particularly focused on addressing the substantial unmet needs of birthing...

Continue Reading